An observational study in Warfarin Sodium Causing Adverse Effects in Therapeutic Use, sponsored by Haobin Li. Completed at 1 site in China. Open to participants aged 65 Years to 100 Years. Per ClinicalTrials.gov, last updated 2024-05-29.
Sponsored by Haobin Li · Observational
Analyze the impact of the degree of blood vessel aging on the anticoagulant effect and bleeding risk of warfarin. Evaluating the possibility of using the degree of blood vessel aging to guide individualized use of the anticoagulant drug warfarin.
This is the only study on the registry with Haobin Li as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Patients taking warfarin
Patients aged 65 years and older, taking warfarin, with or without premature vascular aging, regardless of gender.
Patients who have not concurrently or intermittently used anticoagulant drugs, including antiplatelet drugs, heparin, low molecular weight heparin, and non-vitamin K-dependent oral anticoagulants, such as dabigatran and apixaban.
Exclusion Criteria:
Patients who are allergic to warfarin or lactose.
Patients who are receiving immunosuppressive agents or low molecular weight heparin anticoagulants.
Patients with bleeding tendencies, blood disorders with platelet counts > 400 × 10\^9 /L or \< 100 × 10\^9 /L, hemoglobin > 169 or \< 100 g/L.
History of peptic ulcer disease.
Malignant tumors, severe multi-organ dysfunction or failure such as heart, liver, and kidney.
Numbers of patients with bleeding events
Numbers of patients with bleeding events during warfarin treatment
Time frame: 1 year during the follow-up
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.